Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 19

1.

Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients.

Ohguri T, Imada H, Yahara K, Moon SD, Yamaguchi S, Yatera K, Mukae H, Hanagiri T, Tanaka F, Korogi Y.

Lung Cancer. 2012 Jul;77(1):140-5. doi: 10.1016/j.lungcan.2012.02.018. Epub 2012 Mar 23.

PMID:
22445656
2.

Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?

Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A, Han P, Choi K, Rotman M.

Cancer. 2010 Mar 1;116(5):1350-7. doi: 10.1002/cncr.24853.

3.

Re-evaluate the effect of hyperbaric oxygen therapy in cancer - a preclinical therapeutic small animal model study.

Pande S, Sengupta A, Srivastava A, Gude RP, Ingle A.

PLoS One. 2012;7(11):e48432. doi: 10.1371/journal.pone.0048432. Epub 2012 Nov 7.

4.

Is re-irradiation effective in symptomatic local recurrence of non small cell lung cancer patients? A single institution experience and review of the literature.

Cetingoz R, Arican-Alicikus Z, Nur-Demiral A, Durmak-Isman B, Bakis-Altas B, Kinay M.

J BUON. 2009 Jan-Mar;14(1):33-40. Review.

PMID:
19373944
5.

Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer.

Langer W, Sohler F, Leder G, Beckmann G, Seidel H, Gröne J, Hummel M, Sommer A.

BMC Genomics. 2010 Nov 30;11:676. doi: 10.1186/1471-2164-11-676.

6.

Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set.

Fibla JJ, Cassivi SD, Brunelli A, Decker PA, Allen MS, Darling GE, Landreneau RJ, Putnam JB.

Lung Cancer. 2012 Dec;78(3):259-62. doi: 10.1016/j.lungcan.2012.09.010. Epub 2012 Oct 3.

7.

Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.

Blancafort P, Jin J, Frye S.

Mol Pharmacol. 2013 Mar;83(3):563-76. doi: 10.1124/mol.112.080697. Epub 2012 Nov 13. Review.

8.

Re-examination of siRNA specificity questions role of PICH and Tao1 in the spindle checkpoint and identifies Mad2 as a sensitive target for small RNAs.

Hübner NC, Wang LH, Kaulich M, Descombes P, Poser I, Nigg EA.

Chromosoma. 2010 Apr;119(2):149-65. doi: 10.1007/s00412-009-0244-2. Epub 2009 Nov 11.

9.

Molecular dynamics re-refinement of two different small RNA loop structures using the original NMR data suggest a common structure.

Henriksen NM, Davis DR, Cheatham TE 3rd.

J Biomol NMR. 2012 Aug;53(4):321-39. doi: 10.1007/s10858-012-9642-5. Epub 2012 Jun 20.

10.

The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system.

Oliaro A, Filosso PL, Cavallo A, Giobbe R, Mossetti C, Lyberis P, Cristofori RC, Ruffini E.

Eur J Cardiothorac Surg. 2008 Aug;34(2):438-43; discussion 443. doi: 10.1016/j.ejcts.2008.03.070. Epub 2008 May 27. Review.

PMID:
18502660
11.

A biosynthetic strategy for re-engineering the Staphylococcus aureus cell wall with non-native small molecules.

Nelson JW, Chamessian AG, McEnaney PJ, Murelli RP, Kazmierczak BI, Spiegel DA.

ACS Chem Biol. 2010 Dec 17;5(12):1147-55. doi: 10.1021/cb100195d. Epub 2010 Oct 5. Erratum in: ACS Chem Biol. 2011 Sep 16;6(9):971. Kazmiercak, Barbara I [corrected to Kazmierczak, Barbara I].

13.

Sample size re-estimation in an on-going NIH-sponsored clinical trial: the secondary prevention of small subcortical strokes experience.

McClure LA, Szychowski JM, Benavente O, Coffey CS.

Contemp Clin Trials. 2012 Sep;33(5):1088-93. doi: 10.1016/j.cct.2012.06.007. Epub 2012 Jun 30.

14.

18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.

Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Langen HJ, Bares R.

Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):463-71. Epub 2006 Nov 14.

PMID:
17103167
15.

Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

Cohen J, Looney W.

J Natl Cancer Inst. 2010 Aug 4;102(15):1207; author reply 1207-10. doi: 10.1093/jnci/djq246. Epub 2010 Jul 22. No abstract available.

PMID:
20651322
16.

[A case report of multiple adenocarcinoma in small intestine after total gastrectomy by Roux-en-Y re-construction].

Choda Y, Ninomiya M, Fujiwara Y, Kanazawa T, Harano M, Matsukawa H, Ojima Y, Shiozaki S, Ohno S.

Gan To Kagaku Ryoho. 2011 Nov;38(12):2042-4. Japanese.

PMID:
22202278
17.

Re: Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Atala A.

J Urol. 2012 Oct;188(4):1397-8. doi: 10.1016/j.juro.2012.06.074. Epub 2012 Aug 18. No abstract available.

PMID:
22971415
18.

RE: A phase I trial of radiation dose escalation using accelerated concomitant boost radiotherapy concurrently with weekly carboplatin/paclitaxel in patients with good performance status and Stage IIB-IIIA/B non-small cell lung cancer.

Lehman M, Horwood K, Burmeister B, Zarate D, Dauth M.

J Med Imaging Radiat Oncol. 2012 Oct;56(5):574-5. doi: 10.1111/j.1754-9485.2012.02407.x. No abstract available.

PMID:
23043579
19.

Re-challenge chemotherapy for relapsed non-small-cell lung cancer.

Nagano T, Kim YH, Goto K, Kubota K, Ohmatsu H, Niho S, Yoh K, Naito Y, Saijo N, Nishiwaki Y.

Lung Cancer. 2010 Sep;69(3):315-8. doi: 10.1016/j.lungcan.2009.11.016. Epub 2010 Jan 13.

PMID:
20071052

Supplemental Content

Support Center